Medication info
Dapaen Duo Sustained Release Tablet 5/1000 mg

Dapaen Duo Sustained Release Tablet 5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›7.35mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Dark pink, oval-shaped film-coated tablets that are convex on both sides
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202106825 · Approved 2021.10.08 · Insurance code 640007820

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose close to the metformin dose the patient was taking. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering drug. Because changes may result in altered blood glucose control, any change in treatment in patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted through the kidneys, and renal function is more likely to decline in elderly patients; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps control blood sugar in adults with type 2 diabetes by combining dapagliflozin and metformin. It is administered as an adjunct to diet and exercise regimens to effectively manage blood sugar levels. Particularly in patients who have difficulty controlling their blood sugar and have cardiovascular disease or risk factors, it is important to refer to expert guidelines regarding the cardiovascular effects of this drug. This medication is used to improve blood sugar control in type 2 diabetes patients.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose close to the metformin dose the patient was taking. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering drug. Because changes may result in altered blood glucose control, any change in treatment in patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted through the kidneys, and renal function is more likely to decline in elderly patients; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used to lower blood sugar, and caution should be exercised as there is a risk of a rare side effect known as severe lactic acidosis. This drug may cause a risk of hypoglycemia when used with other diabetes medications, so hypoglycemic symptoms should be closely monitored. It should not be administered to patients with impaired renal function, dehydration, or serious infections, and use should be discontinued for a certain period before and after surgery. Pregnant or breastfeeding women should not use this medication, and it should be avoided in patients with a history of hypersensitivity. This drug may cause a reduction in fluid volume or hypotension, so particular attention should be paid to blood pressure and fluid status, especially in elderly patients or those taking diuretics. While taking this medication, genital infections or urinary tract infections may occur, so any related symptoms should be reported to medical personnel immediately. Vitamin B12 levels may decrease, so regular blood tests are necessary if used long term. Alcohol consumption can increase the risk of side effects; therefore, excessive drinking should be avoided during treatment. Dosage adjustments may be necessary if taken with medications that carry a risk of hypoglycemia, and hypoglycemic symptoms should always be closely monitored. Although this medication does not significantly impact the ability to drive or operate machinery, caution is needed as symptoms like dizziness may occur. When storing the medication, keep it out of reach of children and store in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 87 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland masses
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • peritendinitis
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • benign prostatic hyperplasia
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Maintaining the appropriate storage temperature will preserve the effectiveness and safety of the medication for a longer period.

Appearance and packaging

Appearance

Dark pink, oval-shaped film-coated tablets that are convex on both sides

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.